论文部分内容阅读
治疗相关性白血病(Therapy-related Leukemia,TRL)是一个比较新的概念。最初,在1970年由Allan首先报道,以后就有大量病例及研究报道。它是在多种疾病中长期化疗和/或放疗以后发生的一种继发性白血病。虽亦有发生慢性粒细胞白血病的报道,但绝大多数是急性非淋巴细胞白血病(ANLL)。 TRL和一般人群发生的ANLL相比,似有本质不同:(1)它有其原发病,经化疗和/或放疗以后发生的;(2)其治疗缓解率很低,仅6.5%(般人群的ANLL缓解率可高达83%);(3)其染色体异常高达94%(一般人群的ANLL染色体异常为30～50%);(4)常常表现为全骨髓增生。
Therapy-related Leukemia (TRL) is a relatively new concept. Initially, Allan first reported in 1970, there are a large number of cases and research reports. It is a secondary leukemia that occurs after long-term chemotherapy and / or radiotherapy in a variety of diseases. Although there are also reports of chronic myelogenous leukemia, the vast majority are acute non-lymphocytic leukemia (ANLL). There is a qualitative difference between TRL and ANLL occurring in the general population: (1) it has its primary disease that occurs after chemotherapy and / or radiotherapy; (2) it has a very low response rate of 6.5% ( The ANLL rate in the population can be as high as 83%); (3) its chromosomal abnormalities are as high as 94% (ANLL chromosomal abnormalities in the general population are 30-50%); and (4) it is often characterized by whole myeloproliferation.